Cargando…

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder

BACKGROUND: Comorbid anxiety is generally associated with poorer response to antidepressant treatment. This post hoc analysis explored the efficacy of esketamine plus an antidepressant in patients with treatment‐resistant depression (TRD) with or without comorbid anxiety. METHODS: TRANSFORM‐2, a dou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daly, Ella J., Turkoz, Ibrahim, Salvadore, Giacomo, Fedgchin, Maggie, Ionescu, Dawn F., Starr, H. Lynn, Borentain, Stephane, Trivedi, Madhukar H., Thase, Michael E., Singh, Jaskaran B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291524/ https://www.ncbi.nlm.nih.gov/pubmed/34293233 http://dx.doi.org/10.1002/da.23193

Ejemplares similares

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
por: Nijs, Michel, et al.
Publicado: (2020)

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
por: Williamson, David, et al.
Publicado: (2022)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
por: Fedgchin, Maggie, et al.
Publicado: (2019)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
por: Borentain, Stephane, et al.
Publicado: (2022)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
por: Borentain, Stephane, et al.
Publicado: (2021)

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
por: Doty, Richard L., et al.
Publicado: (2021)

Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression
por: Turkoz, Ibrahim, et al.
Publicado: (2021)

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
por: Saad, Ziad, et al.
Publicado: (2020)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
por: Morrison, Randall L., et al.
Publicado: (2018)

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
por: Castro, Meredith, et al.
Publicado: (2023)

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study
por: van de Loo, Aurora J. A. E., et al.
Publicado: (2017)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
por: Fu, Dong-Jing, et al.
Publicado: (2023)

Treatment strategies to improve and sustain remission in major depressive disorder
por: Madhukar H., Trivedi, et al.
Publicado: (2008)

A review of quetiapine in combination with antidepressant therapy in patients with depression
por: Daly, Ella J, et al.
Publicado: (2007)

Genome-wide association study and polygenic risk score analysis of esketamine treatment response
por: Li, Qingqin S., et al.
Publicado: (2020)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
por: Diekamp, Bettina, et al.
Publicado: (2021)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
por: Veraart, J.K.E., et al.
Publicado: (2023)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants
por: Rotroff, D M, et al.
Publicado: (2016)

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Research advances in the clinical application of esketamine
por: Zhang, Xiao‐Xi, et al.
Publicado: (2022)

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
por: Dijkstra, Francis M, et al.
Publicado: (2022)

An epidemiological snapshot of cannabis use and comorbid substance abuse, depression and anxiety in young Romanians
por: Ionescu, T. C., et al.
Publicado: (2023)

The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report
por: Matteo, Marcatili, et al.
Publicado: (2021)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
por: Keeler, Johanna Louise, et al.
Publicado: (2023)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings
por: Trivedi, Madhukar H, et al.
Publicado: (2009)

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)
por: Jamieson, Carol, et al.
Publicado: (2023)

Esketamine clinical trials: reply to Maju et al.
por: Gastaldon, C., et al.
Publicado: (2020)

Comparison between dexmedetomidine and esketamine in pediatric dentistry surgery
por: Xin, Naixing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l1e4rulpqa465s18fnvlpntgi6